Source: Menopause : The Journal of the North American Menopause Society. Unidade: FM
Subjects: INFLAMAÇÃO, TERAPIA DE REPOSIÇÃO DE ESTRÓGENOS, MENOPAUSA (EFEITOS ADVERSOS), FATORES DE RISCO, INTERLEUCINA 6 (ANÁLISE)
ABNT
VITALE, Cristiana et al. Interleukin-6 and flow-mediated dilatation as markers of increased vascular inflammation in women receiving hormone therapy. Menopause : The Journal of the North American Menopause Society, v. 12, n. 5, p. 552-558, 2005Tradução . . Disponível em: https://doi.org/10.1097/01.gme.0000172267.24949.70. Acesso em: 03 nov. 2025.APA
Vitale, C., Cornoldi, A., Gebara, O., Silvestri, A., Wajngarten, M., Cerquetani, E., et al. (2005). Interleukin-6 and flow-mediated dilatation as markers of increased vascular inflammation in women receiving hormone therapy. Menopause : The Journal of the North American Menopause Society, 12( 5), 552-558. doi:10.1097/01.gme.0000172267.24949.70NLM
Vitale C, Cornoldi A, Gebara O, Silvestri A, Wajngarten M, Cerquetani E, Fini M, Ramires JAF, Rosano G. Interleukin-6 and flow-mediated dilatation as markers of increased vascular inflammation in women receiving hormone therapy [Internet]. Menopause : The Journal of the North American Menopause Society. 2005 ; 12( 5): 552-558.[citado 2025 nov. 03 ] Available from: https://doi.org/10.1097/01.gme.0000172267.24949.70Vancouver
Vitale C, Cornoldi A, Gebara O, Silvestri A, Wajngarten M, Cerquetani E, Fini M, Ramires JAF, Rosano G. Interleukin-6 and flow-mediated dilatation as markers of increased vascular inflammation in women receiving hormone therapy [Internet]. Menopause : The Journal of the North American Menopause Society. 2005 ; 12( 5): 552-558.[citado 2025 nov. 03 ] Available from: https://doi.org/10.1097/01.gme.0000172267.24949.70
                    
                    